BriaCell Therapeutics Corp. Stock News

BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 he

PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi

BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?

BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatm

BriaCell Therapeutics (BCTX) announced on Thursday that the company was selected to perform a presentation on off-the-shelf cancer therapies at the American Association for Cancer

BriaCell Therapeutics Corp. (NASDAQ:BCTX) with the stream of 3.88% also noticed, India DigitalBridge Group, Inc. (NYSE:DBRG) encountered a rapid change of -1.36% in the last hour of Thursdays trading session. The post Active Stocks Momentum: BriaCell Therapeutics Corp. (NASDAQ:BCTX), DigitalBridge Group, Inc. (NYSE:DBRG) appeared first on Stocks Equity .

An investor agreed to buy 1.59 million shares, or 10% of its basic common shares

NEW YORK and VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that certain members of its Board of Directors and Management team (the Insiders) have informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Companys basic common shares outstanding.

The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which repre

In the last trading session, 2.4 million shares of the BriaCell Therapeutics Corp. (NASDAQ:BCTX) were traded. Most recently the companys share price was $7.30, and it changed around -$0.6 or -7.59% from the last close, which brings the market valuation of the company to $104.63M. BCTX currently trades at a discount to its 52-week high BriaCell Therapeutics Corp. (NASDAQ: BCTX) Is Something To Consider Today. Read More »

The trading price of BriaCell Therapeutics Corp. (NASDAQ:BCTX) closed lower on Friday, December 10, closing at $7.90, -10.94% lower than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

PALM BEACH, Fla. , Dec. 10, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Ongoing advancements in cancer research continue to lead to the introduction of newer and better treatment options including drug therapies. The provision of newer drugs and treatments is expected to improve the diagnostic and treatment rate for triple-negative breast cancer . Some of the recent clinical efforts are being targeted at the molecular level characterization of triple-negative breast cancer across emerging therapeutic targets such as epigenetic proteins, PARP1, androgen receptors, receptor and non-receptor tyrosine kinases, and immune checkpoints. These initiatives are anticipated to boost revenue growth of the triple-negative breast cancer treatment market. In a new research study, Persistence Market Research estimates the global triple-negative breast cancer treatment market revenue to cross US$ 720 Mn by 2026 from an estimated valuation of just under US$ 505 Mn in 2018. This is indicative of a CAGR of 4.7% during the period 2018 to 2026.

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 The post Overwhelming stocks: BriaCell Therapeutics Corp. (NASDAQ:BCTX -5.24%), The Williams Companies, Inc. (NYSE:WMB -3.69%) appeared first on Stocks Equity .

BriaCell Therapeutics Corp. (NASDAQ:BCTX) price on Wednesday, December 08, fall -0.64% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $9.36. A look at the stock’s price movement, the close in the last trading session was $9.42, moving within a range at $9.21 and $9.97. The beta value … A Stock Analysis Of BriaCell Therapeutics Corp.’s (BCTX) Read More »

NEW YORK and VANCOUVER, British Columbia, Dec. 09, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, presented clinical results from its lead clinical candidate Bria-IMT in a poster session held on December 8, 2021 during the 2021 San Antonio Breast Cancer Symposium ® (SABCS) (the Poster).